Allogene Therapeutics Net Profit Margin Growth & History (ALLO)
Allogene Therapeutics's net profit margin was −1,170,863.64% for fiscal 2024.
View full Allogene Therapeutics company overviewAllogene Therapeutics annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −1,170,863.64% | −826374.16 pp |
| 2023 | 2023-12-31 | −344,489.47% | −126275.37 pp |
| 2022 | 2022-12-31 | −218,214.10% | −218054.53 pp |
| 2021 | 2021-12-31 | −159.57% | — |
Allogene Therapeutics quarterly net profit margin
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −919.76% | — |
| Q1 2024 | 2024-03-31 | −295,454.55% | +37772.12 pp |
| Q4 2023 | 2023-12-31 | −408,466.67% | −34332.05 pp |
| Q3 2023 | 2023-09-30 | −283,122.73% | +28884.68 pp |
| Q2 2023 | 2023-06-30 | −360,145.45% | −234692.33 pp |
| Q1 2023 | 2023-03-31 | −333,226.67% | −131670.26 pp |
| Q4 2022 | 2022-12-31 | −374,134.62% | −374134.73 pp |
| Q3 2022 | 2022-09-30 | −312,007.41% | −152444.14 pp |
| Q2 2022 | 2022-06-30 | −125,453.13% | +35765.06 pp |
| Q1 2022 | 2022-03-31 | −201,556.41% | −201470.31 pp |
| Q4 2021 | 2021-12-31 | 0.11% | — |
| Q3 2021 | 2021-09-30 | −159,563.27% | — |
| Q2 2021 | 2021-06-30 | −161,218.18% | — |
| Q1 2021 | 2021-03-31 | −86.10% | — |
Allogene Therapeutics net profit margin trends
Between the periods ended 2021-12-31 and 2024-12-31, Allogene Therapeutics's net profit margin decreased from −159.57% to −1,170,863.64%, a change of −1170704.07 percentage points. The latest reported quarter, Q2 2026, shows −919.76%.
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Allogene Therapeutics source filings ↗